Clinical

Clinical  ·  Weekly Digest 07 Dec to 13 Dec 2024
GSK multiple myeloma drug’s DREAMM comeback continues with phase 3 data at ASH

Weekly Digest – December 2024 Weekly Digest – December 2024 09 Dec 2024: GSK multiple myeloma drug’s DREAMM comeback continues with phase 3 data at ASH GSK’s Blenrep extended progression-free survival (36.6 months vs. 13.4 months) and duration of response […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest 07 Dec to 13 Dec 2024
Merck’s investigational zilovertamab vedotin in combination with R-CHP demonstrates complete response rate of 100% at 1.75 mg/kg dose in phase 2 trial of previously untreated patients with Diffuse Large B-Cell Lymphoma

Weekly Digest – December 2024 Weekly Digest – December 2024 08 Dec 2024: Merck’s investigational zilovertamab vedotin in combination with R-CHP demonstrates complete response rate of 100% at 1.75 mg/kg dose in phase 2 trial of previously untreated patients with […]

by Sandhya Ramalingam

Continue Reading